Character | Response | |
---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Character | Response | |
---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class | Active | Resistant |
---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
Lineage | Physiology | General | Growth Tolerances | Hydrol./digest./degr. |
|
|
Health: Unknown
Source: clinical sources (blood, nasopharynx- CCUG) and has been detected in human faeces
|
Low T(℃): 5(neg)
High T(℃): 41(+)
|
|
---|
Monosaccharide O/F | Oligosaccharide O/F | Polysaccharide O/F | Polyol O/F | Other O/F |
|
|
|
|
|
---|
Monosaccharide util/assim | Oligosaccharide util/assim | Other carboh. util/assim | Amino acid util/assim | Organic acid util/assim |
|
|
|
|
|
---|
Enzymes: General | Enzymes: Carbohydrate | Enzymes: Protein | Enzymes: Arylamidases | Enzymes: Esters/fats |
|
|
|
|
|
---|
Fuel | Usable Metabolites | Metabolites Released | Special Products | Compounds Produced |
|
---|
Penicillins & Penems (μg/mL) | Cephalosporins (μg/mL) | Aminoglycosides (μg/mL) | Macrolides (μg/mL) | Quinolones (μg/mL) |
Augmentin: S(MIC50): 4, MIC90: 8, RNG: (0.5–8)
piper-taz: S(MIC50): 0.5, MIC90: 0.5, RNG: (0.5–64)
imipenem: S(MIC50): 0.125, MIC90: 0.125, RNG: (0.125–0.25)
|
cefotetan: S(MIC50): 0.5, MIC90: 0.5, RNG: (0.5)
cefoxitin: S(MIC50): 2, MIC90: 2, RNG: (1–2)
|
amikacin: Var(MIC50): ≤0.25->32), MIC90: Var(≤0.25->32
gentamicin: S(MIC50): 0.5, MIC90: 0.5, RNG: (0.5)
|
|
ciprofloxacin: S(MIC50): 0.015, MIC90: 0.03, RNG: (0.015–0.03)
levofloxacin: S(MIC50): 0.015, MIC90: 0.015, RNG: (0.15–0.06)
ofloxacin: S(MIC50): 0.03, MIC90: 0.06, RNG: (0.015–0.125)
trovafloxacin: S(MIC50): 0.03, MIC90: 0.06, RNG: (0.015–0.06)
|
---|---|---|---|---|
Tetracyclines (μg/mL) | Vancomycin Class (μg/mL) | Polypep/ketides (μg/mL) | Heterocycles (μg/mL) | Other (μg/mL) |
|
|
|
|
|